+Hosted content | New Zealand Doctor

This website is intended for a health professional readership

Our Hosted Content space gives companies, agencies and organisations the opportunity to tell their stories through having their content hosted on the New Zealand Doctor site. Read our Terms of Use statement with regard to the use of third party content on our site.

GALVUS® and GALVUMET® STILL FULLY FUNDED

GALVUS and GALVUMET remain an effective, subsidised treatment strategy for your type 2 diabetes patient not reaching their HbA1c target^1-3

Novartis New Zealand

Wednesday 10 February 2021, 01:27 PM

Why urgency is needed when managing “stable” heart failure patients such as Bernard

Bernard is typical of most heart failure patients seen in general practice – mildly symptomatic (NYHA Class II)²

Supplied by Novartis New Zealand Limited

Saturday 1 August 2020, 06:00 AM

What more can I do for my heart failure patient?

Practical tips for GPs switching an HFrEF patient to ENTRESTO from an ACEi or ARB

Supplied by Novartis New Zealand Limited

Thursday 30 April 2020, 10:26 AM

Targeting the feet as a common source of everyday lower body pains

Over a lifetime, an active person can walk the equivalent distance of five times around the equator!¹

Brought to you by Scholl In-Balance®

Monday 9 December 2019, 02:57 PM

Having compliance problems with insulin?

Click here for V-Go^® free trial.

Are you treating your type 2 diabetes patients with insulin and do they still struggle to achieve their HbA1C target? Insulin injections might make patients feel uncomfortable in social circumstances while others are needle phobic, leading to poor compliance and increases in HbA1C

By NZMS Diabetes

Thursday 27 June 2019, 10:33 AM

Another view on the patients you see too often

Some of your patients just seem more susceptible to seasonal complaints than others. Could their bacterial balance be out of whack?

Dr John Tagg, Professor Emeritus at University of Otago

Thursday 21 September 2017, 12:09 PM